Journal profile · Pharmacology & Pharmacy
Journal of Pharmacological Sciences
ISSN 1347-8613 · eISSN 1347-8648 · Japanese Pharmacological Society · JAPAN · Monthly · Founded 2003
Journal of Pharmacological Sciences: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.79; fully open access; APC about USD 2,760; median 95 days to acceptance (104 articles, last 24 months); community-reported acceptance: easy; 116 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Pharmacological Sciences is published by Japanese Pharmacological Society and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Neuroscience and Neuropharmacology Research, Ion channel regulation and function and Receptor Mechanisms and Signaling, together about 28.1% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Official Journal of the Japanese Pharmacological SocietyJournal of Pharmacological Sciences (JPS), an official journal of the Japanese Pharmacological Society, is an international open access journal intended for the advancement of pharmacological sciences in the world. The journal welcomes submissions in all fields of experimental and clinical pharmacology, including molecular, cellular, biochemical, physiological and behavioral pharmacology, for publication as "Reviews", "Full Papers" or "Short communications". Review articles are only accepted if they are requested by the editors. Short communications will only be accepted for papers that present novel and highly exciting pharmacological findings. Manuscripts concerning descriptive case reports, pharmacokinetic and pharmacodynamic studies without pharmacological mechanisms and dose-response determinations are not acceptable and will be rejected without peer review. Ethnopharmacological studies are also out of the scope of this journal. Furthermore, JPS does not publish work on the actions of biological extracts unknown chemical composition.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Yasunari KandaPublisher website
Editorial board by country: 9 in mainland China (about 12%); most named Japan 53, Mainland China 9, United States 5, South Korea 2, Thailand 2 (73 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Neuroscience and Neuropharmacology ResearchNeuroscience10.5%
- Ion channel regulation and functionBiochemistry, Genetics and Molecular Biology9.3%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology8.3%
- Cardiac electrophysiology and arrhythmiasMedicine7%
- Nitric Oxide and Endothelin EffectsMedicine5.6%
- Pain Mechanisms and TreatmentsMedicine5.1%
- Neuropeptides and Animal PhysiologyNeuroscience5.1%
- Legal and Regulatory AnalysisSocial Sciences4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.79LetPub ·
- Impact factor (publisher)
- 2.8Publisher website ·
- CiteScore 2026-06
- 5.7LetPub ·
- CiteScore (publisher)
- 5.7Publisher website ·
- SJR 2026-06
- 0.89LetPub ·
- SNIP 2026-06
- 0.81LetPub ·
- h-index
- 74LetPub ·
- h-index
- 107OpenAlex ·
- i10-index
- 2,393OpenAlex ·
- 2-year mean citedness
- 3.03OpenAlex ·
- Self-citation rate
- 10.7%LetPub ·
- Share of gold OA articles
- 99.26%LetPub ·
Volume
- Articles per year
- 109LetPub ·
Articles by year OpenAlex count · 3,837 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 56 | 56 | 12 |
| 2025 | 116 | 116 | 316 |
| 2024 | 83 | 83 | 445 |
| 2023 | 77 | 77 | 678 |
| 2022 | 96 | 96 | 1,078 |
| 2021 | 122 | 122 | 2,237 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
95 daysMedian, submission to acceptance · P25–P75 70 days – 127 days
- Acceptance to online
- median 1 days (104 articles)
- Submission to online
- median 96 days
- Sample
- 104 articles with submission and acceptance dates (195 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–8 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Submission to first decision
- 6 daysPublisher website ·
- First decision after review
- 22 daysPublisher website ·
- Submission to acceptance
- 79 daysPublisher website ·
- Acceptance to publication
- 1 daysPublisher website ·
- Submission to publication (journal-reported)
- about 12 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,760 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 2,070 / EUR 1,940 / GBP 1,660 / JPY 256,740 | — | — | |
| LetPub | USD 2,070 | Yes | — | |
| Publisher website | USD 2,760 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- ≤ 200 words
- Keywords
- 3–5
- Reference style
- AMA
- Graphical abstract
- Optional
Article types accepted3
- full papersfor publication as Reviews, Full Papers, or Short CommunicationsLength not stated
- reviewsfor publication as Reviews, Full Papers, or Short CommunicationsLength not stated
- short communicationsfor publication as Reviews, Full Papers, or Short CommunicationsLength not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Preprints, Trial registration / reporting guidelines
- AI use Declaration of generative AI in scientific writing
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship 6.8. Author Contributions:
A statement outlining the specific contributions of each author (CRediT taxonomy recommended).
Source ↗Publisher website ·- Conflicts of interest 6.6. Conflict of Interest (COI) Disclosure:
A statement disclosing all potential conflicts of interest for all authors, or confirming that none exist.
Source ↗Publisher website ·- Data availability 6.9. Data Availability Statement:
Data availability statement recommended Model summary
Statement indicating how and where the research data can be accessed or explaining limitations on availability.
Source ↗Publisher website ·- Publication ethics
No duplicate submissions Model summary
Submissions that have been published or accepted, or are under consideration for publication, with essentially the same content, will not be considered.
Source ↗Publisher website ·- License & copyright Copyright
Exclusive License Agreement upon acceptance Model summary
Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (more information). Permitted third party reuse of open access articles is determined by the author's choice of user license.Author rightsAs an author you (or your employer or institution) have certain rights to reuse your work. More information.
Source ↗Publisher website ·- Open access Open access
Please visit our Open Access page for more information about open access publishing in this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor'…
Source ↗Publisher website ·- Preprints Preprint references
Preprint referencing policy Model summary
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the nam…
Source ↗Publisher website ·- Trial registration / reporting guidelines 4.7. Clinical Trial Registration:
Interventional clinical trials must be registered prospectively in a publicly accessible registry (e.g., ClinicalTrials.gov, UMIN-CTR, ISRCTN) before the enrollment of the first participant. The registration number must be provided.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Japanese Pharmacological Society
- Country or region
- JAPAN
- Language
- English
- Frequency
- Monthly
- Founded
- 2003
- ISSN
- 1347-8613
- Electronic ISSN
- 1347-8648
- Society / sponsor
- Japanese Pharmacological Society
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Journal of Pharmacological Sciences
What CAS zone is Journal of Pharmacological Sciences in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Pharmacological Sciences is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Pharmacological Sciences?
The latest impact factor listed by LetPub is 2.79; CiteScore 5.7, h-index 107.
How long does peer review take at Journal of Pharmacological Sciences?
Based on the dates recorded on 104 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 95 days (interquartile range 70–127 days); authors report an average review time of 3–8 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Journal of Pharmacological Sciences?
According to the journal's author guidelines: Abstract: ≤ 200 words; Keywords: 3–5; Reference style: AMA; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Journal of Pharmacological Sciences based?
Of the 73 board members whose country the journal's board page names, 9 (about 12%) are in mainland China; the countries named most often are Japan (53), Mainland China (9) and United States (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Pharmacological Sciences?
According to LetPub and DOAJ records, Journal of Pharmacological Sciences is indexed in SCIE, Scopus and DOAJ.
Is Journal of Pharmacological Sciences open access, and what is the APC?
Journal of Pharmacological Sciences is a fully open-access journal. APC about USD 2,760.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .